DexCom reports higher 2025 sales and reaffirms 2026 revenue outlook
DexCom reported fourth-quarter 2025 revenue of US$1.26 billion and net income of US$267.3 million, with full-year sales of US$4.66 billion. The company reaffirmed 2026 revenue guidance of US$5.16–US$5.25 billion and targeted a non-GAAP operating margin of about 22–23%.
DexCom, Inc. reported fourth-quarter 2025 revenue of US$1,259.6 million and net income of US$267.3 million, alongside full-year 2025 sales of US$4.66 billion and net income of US$836.3 million, all ahead of the prior year. The company also reported improved operating margins and reiterated its 2026 revenue outlook of US$5.16–US$5.25 billion.
The reiterated 2026 outlook was paired with a targeted non-GAAP operating margin of about 22–23%. The company said progress on AI-enhanced products like Stelo and the G7 15-day CGM system supports its focus on both technology and efficiency.
The update highlighted operating scale improvements and product innovation, including the G7 15-day system and AI features in Stelo, which are intended to support both growth in the expanding type 2 opportunity and better profitability. The company’s narrative projects $6.5 billion revenue and $1.4 billion earnings by 2028.
The source article said the biggest risk remains future pricing pressure and competitive threats in core CGM markets. It also said future CMS competitive bidding for CGM devices could affect the outlook.